Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Next Previous
Trial Profile

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Diphenhydramine (Primary) ; Diphenhydramine (Primary) ; Paracetamol (Primary) ; Vibecotamab (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Xencor

Most Recent Events

  • 25 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 12 Dec 2023 Results evaluating vibecotamab in other low-blast states, including MDS or CMML after hypomethylating agent failure and MRD-positive AML, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 07 Dec 2023 Planned number of patients changed from 40 to 42.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top